Arcturus Therapeutics Ltd (NASDAQ:ARCT) has been given an average recommendation of “Buy” by the six research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $12.00.
A number of research analysts have recently weighed in on the company. ValuEngine lowered Arcturus Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 8th. Brookline Cap M restated a “buy” rating on shares of Arcturus Therapeutics in a report on Thursday, September 27th. WBB Securities upgraded Arcturus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 20th. Finally, Zacks Investment Research upgraded Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st.
Shares of ARCT stock traded down $0.21 during trading hours on Wednesday, reaching $6.69. The company had a trading volume of 5,076 shares, compared to its average volume of 22,432. Arcturus Therapeutics has a 12 month low of $4.78 and a 12 month high of $12.25. The firm has a market capitalization of $74.13 million, a PE ratio of -1.90 and a beta of 1.26.
An institutional investor recently bought a new position in Arcturus Therapeutics stock. BlackRock Inc. purchased a new position in shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 19,905 shares of the biotechnology company’s stock, valued at approximately $169,000. BlackRock Inc. owned 0.19% of Arcturus Therapeutics at the end of the most recent quarter. 7.65% of the stock is currently owned by hedge funds and other institutional investors.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
See Also: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.